Nov 17, 2016 - Govt actions are promising for growth, says Jack Ringquist of Deloitte

TradeBriefs Newsletter
View online   Advertise
              from TradeBriefs FMCG Weekly






Sree Vijaykumar
Sree Vijaykumar
From the Editor's Desk
While the world debates the ethical implications of gene editing, a group of Chinese scientists have injected a human being with cells genetically edited using CRISPR-Cas9 technology. The scientists from China are hoping the genetically edited cells will help their patient fend off a virulent type of lung cancer. Another group of Chinese scientists already ran CRISPR experiments on human embryos that didn't go very well - at least two-thirds of the embryos were found to have genetic mutations and only a fraction of the 28 surviving embryos (out of 86 total tested) contained the replacement genetic material. These are among the first human trials in the world. More here

Advertisers of the day
The Economist: Subscribe now and get a Hidesign passport wallet free
BMW: Celebrate joy with BMW Festival 2016  

Our advertisers help fund the daily operations of TradeBriefs. We request you to accept our promotional emails (B2B Decision-Makers, B2C Decision-Makers, TradeBriefs Premium).


Why FMCG companies need distribution aggregators to scale

The FMCG sector is large and relatively unorganised. Following a traditional distribution network is hampering its growth. Here’s how one can bridge the gap.

Read More



Today's TradeBriefs Cartoon

Advt: Work for the best employer - Yourself
reseller
Advantages - Best B2B audience in India, no hard-selling or up-front costs involved, access to our content repository and air-tight agreements with instant gratification.


Britannia holds back product launches, expects demand revival in 9-12 months

Britannia Industries has postponed product launches and expects consumption to revive in 9-12 months.

Read More

NCLAT extends deadline to December 16 for implementation of Patanjali's bid for Ruchi Soya

NCLT had admitted the insolvency plea filed by two lead financial creditors Standard Chartered Bank and DBS Bank. However, later the Singapore-based DBS Bank became dissenting creditor and approached NCLAT challenging the distribution of proceeds from the bid submitted by Baba Ramdev-led Patanjali Ayurveda.

Read More

[Funding alert] Health food brand ‘And Nothing Else’ raises seed funding led by Matrix Partners India

Shashank Mehta, Founder of And Nothing Else, said the funds would be used to scale up quality hiring and build the company's manufacturing capability.

Read More

TradeBriefs Publications are read by over 10,00,000 Industry Executives
About Us  |  Advertise Privacy Policy    

You are receiving this mail because of your subscription with TradeBriefs.
Our mailing address is GF 25/39, West Patel Nagar, New Delhi 110008, India